Radiochemical purity of iodine-131 labelled metaiodobenzylguanidine infusion fluids: a report from clinical practice.
Iodine-131 labelled metaiodobenzylguanidine ([131I]MIBG) has a diagnostic and therapeutic role in the management of neural crest tumours, particularly neuroblastoma, malignant phaeochromocytoma and paraganglioma. With therapeutic amounts of [131I]MIBG it is essential that the amount of free [131I]iodide, the most important impurity, is known. In clinical practice the percentage of free [131I]iodide seen in a [131I]MIBG infusion concentrate increased from 2.2% +/- 0.67% to 3.6% +/- 0.39% (mean +/- SD; n = 23) 1 day after production. At the time of use the percentage of free [131I]iodide was always below our upper limit of acceptance of 5%. Since 5% of free [131I]iodide is within practical reach in our environment, a higher percentage at the time of preadministration quality control is not accepted in the Netherlands Cancer Institute.
Wafelman
A R
AR
Department of Pharmacy, Slotervaart Hospital, Amsterdam, The Netherlands.
Suchi
R
R
Hoefnagel
C A
CA
Beijnen
J H
JH
D019797:3-Iodobenzylguanidine; D003287:Contrast Media; D006801:Humans; D007454:Iodides / Q000032:analysis*; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000008:administration & dosage / Q000627:therapeutic use*
D003287:Contrast Media; D007454:Iodides; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine